Pascale Marty-Ethgen, Pharm.D., Ph.D. is Vice President, Immunology Therapeutic Area Portfolio Management and External Innovation Leader for Janssen Research & Development, LLC. In this role, Pascale is responsible for implementation of the Immunology portfolio strategy, and for all aspects of portfolio management. She also leads the development and implementation of the external innovation strategy, ensuring that Janssen Immunology has access to cutting-edge, transformational external innovation, while promoting excellence in the evaluation of external assets and oversight of alliance management for the pre-clinical external portfolio.
Pascale joined Janssen in January 2015 as Vice President, Compound Development Team Leader for STELARA® (ustekinumab) where she had accountability for all research and development and lifecycle management activities for the drug. Most notably, Pascale led the team that delivered the global submission and approval in two new indications, as well as the progression of a third indication to a global Phase 3 program.
Pascale has more than 25 years of experience in the pharmaceutical industry in roles spanning portfolio strategy, commercial strategy, research and development and business development in biotechnology, consulting for multi-national companies in France, the United Kingdom, and the United States. She has a proven track record of leading global, matrixed teams developing new medicines through to product registration and launch. She also possesses extensive business development experience, including due diligence and management of strategic alliances and virtual drug discovery partnerships.
Prior to joining Janssen, Pascale spent 12 years at GlaxoSmithKline where she held several positions of increasing responsibility across a broad range of therapeutic areas.
Pascale received her Pharm.D. from the University of Bordeaux, France and her Ph.D. in Pharmacology from the University of Marseille, France.
Follow Pascale on LinkedIn here.